Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0465131078
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00QFYX914
ATRA
Atara Biotherapeutics, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Atara Biotherapeutics, Inc.
ISIN
US0465131078
TICKER
ATRA
MIC
XNAS
REUTERS
ATRA.OQ
BLOOMBERG
ATRA US
Wed, 25.03.2026       Atara Biotherapeutics
US0465131078

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Atara Biotherapeutics
US0465131078

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) securities during the period of May 20, 2024 through January 9, 2026, inclusive (“the Class Period”). If you suffered a loss on your Atara investments, y...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Atara Biotherapeutics
US0465131078

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases i...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Atara Biotherapeutics
US0465131078

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the Unite...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates. “We continue...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to dis...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner Pierre Fabre Pharmaceuticals (PFP) has submitted a request to the FDA for a Typ...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement da...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates. Tabelecleucel (tab-cel® or E...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 04.09.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is t...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Atara Biotherapeutics
US0465131078

First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transpla...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics Licens...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       Atara Biotherapeutics
US0465131078

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after failure of standard...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administ...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 17.05.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following th...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates. “We are pleased that we have...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 p...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.05.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara’s active...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.03.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, business updates, and key upcoming m...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 14.02.2025       Atara Biotherapeutics
US0465131078

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION  NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       Atara Biotherapeutics
US0465131078

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 1,350 restricted stock units of Atara’s common stock to one newly hired employee. Th...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       Atara Biotherapeutics
US0465131078

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.01.2025       Atara Biotherapeutics
US0465131078

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       Atara Biotherapeutics
US0465131078

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ: ATRA) for violations of the securities laws....
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.01.2025       Atara Biotherapeutics
US0465131078

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       Atara Biotherapeutics
US0465131078

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.01.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Atara’s active In...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.01.2025       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) fo...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.11.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.11.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2024, recent business highlights, and key upcoming milest...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.11.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 04.10.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,500 restricted stock units of Atara’s common stock to one newly hired employee. Th...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.09.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,700 restricted stock units of Atara’s common stock to one newly hired employee. Th...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.09.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, wi...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.09.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into definitive agreements for the issuance and sale of 758,900 shares of it...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.08.2024       Atara Biotherapeutics
US0465131078

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming miles...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.06.2024       Atara Biotherapeutics
US0465131078

Das Instrument US0465131078 ATARA BIOTHERAP. DL-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 20.06.2024 The instrument US0465131078 ATARA BIOTHERAP. DL-,0001 EQUITY is traded ex capital adjustment on 20.06.2024...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.06.2024       Atara Biotherapeutics
US0465131078

Instrument ID [7547] (AT2 - US0465131078) suspended...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.06.2024       Atara Biotherapeutics
US0465131078

Das Instrument AT2 US0465131078 ATARA BIOTHERAP. DL-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 19.06.2024 und ex Kapitalmassnahme am 20.06.2024 The instrument AT2 US0465131078 ATARA BIOTHERAP. DL-,0001 EQUITY is traded cum capital adjustment on 19.06.2024 and ex capital adjustment on 20.06.2024...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.07.2022       Atara Biotherapeutics
US0465131078

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws. On November 4, 2021, Atara issued a press release touting its T cell immunotherapy p...
Read more
Atara Biotherapeutics
Technical Analysis Termsheets Terminal
Permalink